USE OF A COMPOUND OR COMPOSITION COMPRISING AN INHIBITOR OF NLRP1 INFLAMMASOME ACTIVATION FOR THE TREATMENT OF HUMAN AIRWAY INFLAMMATION

摘要

The present invention relates to a method of prophylaxis or treatment of airway inflammation and/or related complications triggered by Enterovirus 3C protease-activated NLRP1 by using a compound or composition comprising an inhibitor of NLRP1 inflammasome activation. In one embodiment, the Enterovirus 3C protease is from a virus species selected from the group comprising human enterovirus A (HEV-A), human enterovirus B (HEV-B), human enterovirus C (HEV-C), human enterovirus D (HEV-D), human rhinovirus A (HRV-A), human rhinovirus B (HRV-B), and human rhinovirus C (HRV-C). In some embodiments, the compound is selected from the group comprising MLN4924, TAS4464, ZM223, MG132, and Bortezomib.